AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$VRDN

Tousignant Jennifer sold $348K of VRDN

Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares of Viridian Therapeutics, Inc.\DE (VRDN) at $24.50 ($0.35M total) across 2 trades on 2026-08-19.

Original reporting
SEC EDGAR · Tousignant Jennifer
Published Aug 21, 2026, 12:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$VRDN
Neutral
medium confidence
Mentioned
$VRDN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRDNNeutralLow
01

Why it matters

The disclosure is the first public report of this insider transaction, but the modest size limits material impact.

02

Market read

Small insider sell; unlikely to move the stock significantly.

03

What to watch

No other insiders sold; company may still have strong pipeline.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑08‑19

Background

Form 4 filing by Viridian Therapeutics' Chief Legal Officer discloses a complete exit from the company's stock.

Company-level read

Ticker impact

$VRDNNeutralMedium confidence
Context

Chief Legal Officer sold 14,212 shares for $348,194, reducing holdings to zero.

Expected impact

Minimal short-term impact; possible slight downward pressure.

Evidence & confidence

The sale is a primary Form 4 filing but involves a small amount relative to market cap, limiting trading relevance.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to VRDN shareholders.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Viridian Therapeutics, Inc.

    Biotech firm listed on NASDAQ under VRDN.

  • Insider
    Jennifer Tousignant

    Chief Legal Officer of Viridian Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VRDN insider trading history →

Related articles

AUG 6
$VRDNMed

Viridian Therapeutics, Inc.\DE (VRDN): Results of Operations and Financial Condition

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S

SEC EDGAR 8-K5 min
JUL 21
$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

biopharmadive.com7 min
JUL 2
$VRTXMed

Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

rttnews.com7 min
JUN 27
$VRDNHighAI 10/10

Viridian Wins FDA Approval For Lumvoa In Thyroid Eye Disease; Stock Up

Viridian Therapeutics said the U.S. FDA approved Lumvoa (veligrotug-vvze) for thyroid eye disease, its first commercial product. The company said the approval is based on Phase 3 THRIVE and THRIVE-2 trials, which met primary and secondary endpoints with improvements at week 15 in active and chronic TED. Lumvoa is a 12-week course. Viridian added that VRDN stock rose to $17.90 Friday and $19.81 after hours.

rttnews.com3 min